Revisiting the public health implications of the United States–Mexico– Canada agreement

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)Letterpeer-review

View graph of relations

Related Research Unit(s)


Original languageEnglish
Article number50
Number of pages2
Journal / PublicationGlobalization and Health
Online published5 Jun 2020
Publication statusPublished - 2020



This commentary re-examines a recent article by Labonté et al on the recent changes to two relevant provisions relating to patent rights in the final version of the United-States-Mexico-Canada Agreement (USMCA). Although the USMCA’s final revised version does not add more pharmaceutical patent protection than those that already exist in the three trading partners, the agreement has done little to enhance access to generic medicines and biosimilars.

Research Area(s)

  • Public health, USMCA, Pharmaceutical patent, Biologics

Download Statistics

No data available